This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:physicians:concerns [05.26.2019] – [Recorded success rates] sallieq | home:physicians:concerns [07.13.2019] – [Concerns about immunopathology] sallieq | ||
---|---|---|---|
Line 1: | Line 1: | ||
====== Physicians' | ====== Physicians' | ||
+ | |||
+ | < | ||
Over the years, physicians have voiced various concerns about the Marshall Protocol, concerns ranging from the safety of higher doses of olmesartan (Benicar) to concerns about long-term antibiotic use. The Autoimmunity Research Foundation has assembled articles, well-grounded in scientific research, which address these concerns. Physicians who choose to use and administer the MP do so on the basis of the [[home: | Over the years, physicians have voiced various concerns about the Marshall Protocol, concerns ranging from the safety of higher doses of olmesartan (Benicar) to concerns about long-term antibiotic use. The Autoimmunity Research Foundation has assembled articles, well-grounded in scientific research, which address these concerns. Physicians who choose to use and administer the MP do so on the basis of the [[home: | ||
Line 5: | Line 7: | ||
===== Concerns about lack of clinical evidence ===== | ===== Concerns about lack of clinical evidence ===== | ||
- | - **" | + | - **" |
* a [[home: | * a [[home: | ||
* a [[home: | * a [[home: | ||
Line 15: | Line 17: | ||
For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment: | For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment: | ||
- | * evidence | + | * alternative hypotheses and evidence of research |
- | * more recent material | + | * evidence for the efficacy of MP versus other available treatment in 2013 data on patient response, see section |
* patients' | * patients' | ||
* additional benefits of Olmesartan [[https:// | * additional benefits of Olmesartan [[https:// | ||
Line 25: | Line 27: | ||
< | < | ||
- | ===== Recorded | + | ==== Recorded |
< | < | ||
Line 79: | Line 81: | ||
- **"A temporary increase in symptoms or laboratory values means the treatment is not working." | - **"A temporary increase in symptoms or laboratory values means the treatment is not working." | ||
+ | |||
+ | see also [[home: | ||
===== Concerns about antibiotics===== | ===== Concerns about antibiotics===== | ||
Line 113: | Line 117: | ||
- | {{tag> | + | {{tag> |
+ | |||
+ | [[home: | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||